viral
strain
respons
smallpox
infect
variola
major
varv
result
success
erad
smallpox
vaccinia
viru
vacv
gener
popul
longer
requir
receiv
smallpox
vaccin
protect
smallpox
lack
immun
concern
due
potenti
use
smallpox
biolog
weapon
consider
progress
made
develop
subunitbas
smallpox
vaccin
result
identif
vacv
protect
antigen
also
offer
possibl
use
antigen
varv
formul
next
gener
subunitbas
smallpox
vaccin
show
codonoptim
dna
vaccin
express
three
varv
antigen
recombin
protein
counterpart
elicit
hightit
crossreact
vacv
neutral
antibodi
respons
mice
vaccin
mice
protect
intraperiton
intranas
challeng
vacv
result
suggest
feasibl
subunit
smallpox
vaccin
base
varv
antigen
sequenc
induc
immun
poxviru
infect
origin
smallpox
vaccin
base
live
attenu
vaccinia
viru
vacv
erad
smallpox
worldwid
human
popul
last
case
natur
smallpox
infect
occur
somalia
howev
due
safeti
concern
manufactur
tradit
vacv
vaccin
product
type
vaccin
dryvax
wyeth
laboratori
inc
unit
state
deriv
nycbh
strain
vaccinia
viru
longer
consid
accept
sinc
termin
product
report
advers
event
includ
myocard
associ
immun
vacv
casey
et
al
prevent
complet
revaccin
campaign
among
nonmilitari
highrisk
popul
healthcar
profession
current
vacv
still
main
smallpox
vaccin
newer
gener
liveattenu
vacv
vaccin
produc
tissu
cultur
cell
allow
stockpil
hope
abl
protect
gener
popul
event
bioterrorist
attack
artenstein
et
al
fang
et
al
monath
et
al
recent
studi
made
great
stride
demonstr
use
subunitbas
smallpox
vaccin
induc
protect
immun
smallpox
poxvirus
includ
variola
major
varv
vaccinia
viru
vacv
monkeypox
viru
ectromelia
viru
ectv
other
belong
orthopoxviru
genu
consider
crossprotect
observ
virus
poxvirus
larg
virus
genom
encod
protein
complex
partli
delay
identif
protect
antigen
virus
sever
potenti
target
protect
immun
recent
confirm
well
organ
anim
studi
two
form
infecti
poxviru
intracellular
matur
viru
imv
extracellular
envelop
viru
eev
recent
studi
shown
vaccinia
viru
imvspecif
antigen
eevspecif
antigen
immunogen
protect
albeit
variabl
vacv
infect
mice
fogg
et
al
galmich
et
al
hooper
et
al
hooper
et
al
pulford
et
al
sakhatskyy
et
al
xiao
et
al
ectromelia
viru
ectv
xiao
et
al
monkeypox
nonhuman
primat
heraud
et
al
hooper
et
al
furthermor
fourgen
combin
dna
vaccin
encod
two
imv
two
eev
antigen
protect
vaccinia
viru
challeng
mice
induc
antibodi
respons
monkeypox
viru
nonhuman
primat
hooper
custer
thompson
howev
subunit
vaccin
protect
liveattenu
vaccinia
viru
vaccin
unless
polyval
formul
andor
multipl
immun
use
achiev
compar
level
protect
induc
one
singl
vaccinia
inocul
fogg
et
al
hooper
et
al
hooper
custer
thompson
pulford
et
al
sakhatskyy
et
al
livevaccinia
viru
vaccin
offer
better
protect
infect
unclear
studi
conduct
examin
contribut
two
arm
immun
system
offer
protect
immun
poxviru
infect
deplet
band
tcell
prior
primari
andor
secondari
challeng
variou
poxvirus
offer
conflict
result
antibodymedi
deplet
bcell
tcell
prevent
vaccineinduc
protect
lethal
intraven
challeng
monkeypox
viru
edghillsmith
et
al
poxviru
mous
model
belyakov
et
al
indic
protect
respons
primarili
mediat
antibodi
vacciniainduc
antibodi
necessari
suffici
protect
lethal
poxviru
challeng
addit
result
confirm
role
antibodi
respons
show
passiv
administr
vacv
antibodi
confer
protect
subsequ
lethal
monkeypox
edghillsmith
et
al
hooper
et
al
type
iii
ifn
defici
deplet
mice
abl
surviv
secondari
infect
ectv
panchanathan
chaudhri
karupiah
howev
determin
immun
respons
primari
secondari
vaccin
smallpox
human
recent
studi
shown
posit
cmi
respons
could
elicit
seven
day
infect
secondari
immun
volunt
ie
vaccinia
respons
preced
increas
antibodi
titer
kennedi
et
al
furthermor
import
role
interferon
ifn
less
role
antibodi
confer
protect
poxviru
observ
follow
primari
infect
panchanathan
chaudhri
karupiah
pulford
et
al
exact
role
arm
immun
system
mediat
poxviru
infect
complet
elucid
major
recent
report
point
greater
role
antibodi
variou
poxviru
antigen
elicit
protect
poxviru
infect
therefor
appear
though
subunitbas
smallpox
vaccin
induc
poxvirusspecif
antibodi
would
effect
confer
protect
poxviru
infect
although
poxvirus
highli
conserv
region
encod
protect
antigen
clear
whether
antibodi
induc
variola
antigen
may
confer
higher
level
protect
homolog
challeng
compar
respons
induc
vaccinia
antigen
recent
studi
examin
differ
major
neutral
antigen
site
vaccinia
viru
variola
viru
ortholog
demonstr
panel
monoclon
antibodi
cross
react
protein
least
eev
neutral
block
comet
format
aldazcarrol
result
indic
product
subunitbas
vaccin
use
varv
antigen
rather
vacv
may
confer
greater
protect
smallpox
infect
appar
reason
use
varv
antigen
subunitbas
vaccin
safeti
issu
use
variola
viru
live
attenu
vaccin
lead
use
antigen
vaccinia
viru
product
subunitbas
vaccin
incorpor
live
virus
design
therefor
elimin
safeti
concern
use
variola
viru
antigen
goal
current
studi
demonstr
feasibl
produc
subunit
smallpox
vaccin
base
varv
antigen
sequenc
least
theori
approach
minim
chanc
reduc
protect
due
sequenc
differ
may
exist
varv
vacv
particularli
antigenspecif
immun
respons
neutral
antibodi
determin
andor
domin
tcell
epitop
involv
current
studi
three
varv
antigen
chosen
base
high
immunogen
potenti
protect
vacv
counterpart
shown
literatur
recent
publish
studi
sakhatskyy
et
al
amino
acid
sequenc
three
wellcharacter
protect
antigen
vacv
compar
ortholog
protein
varv
viru
fig
vacv
sequenc
two
frequent
use
strain
western
reserv
wr
copenhagen
cop
includ
analysi
varv
india
varvind
bangladesh
varvbsh
strain
sequenc
use
ortholog
varv
protein
vacv
antigen
varvind
varvbsh
antigen
ortholog
protein
varvind
varvbsh
antigen
ortholog
protein
varvind
varvbsh
shchelkunov
shchelkunov
massung
esposito
sequenc
three
protein
highli
homolog
complet
ident
vacv
antigen
sequenc
three
amino
acid
differ
exist
amino
acid
differ
amino
acid
differ
protein
fig
differ
occur
one
two
varv
strain
therebi
improv
overal
level
homolog
codon
modifi
gene
varvind
chemic
synthes
without
involv
actual
variola
viru
although
final
codon
chang
amino
acid
code
procedur
increas
frequenc
codon
use
mammalian
cell
shown
potenti
improv
antigen
express
immunogen
dna
vaccin
haa
park
seed
wang
et
al
synthet
gene
code
varv
protein
individu
clone
dna
vaccin
vector
use
cmv
ie
promot
drive
express
code
antigen
insert
wang
et
al
addit
place
behind
human
tissu
plasminogen
activ
tpa
leader
sequenc
shown
effect
improv
antigen
express
antigen
immunogen
dna
vaccin
dna
vaccin
encod
fulllength
protein
dna
vaccin
express
ectodomain
fulllength
dna
vaccin
achiev
good
antigen
express
data
shown
express
codonoptim
varv
antigen
dna
vaccin
verifi
cultur
supernat
cell
lysat
cell
transient
transfect
three
varv
antigen
dna
plasmid
examin
western
blot
use
polyclon
antivaccinia
viru
serum
fig
three
antigen
present
cell
lysat
l
cultur
supernat
molecular
weight
gener
match
vacvwr
strain
grown
vero
cell
except
dna
vaccin
express
smaller
molecular
weight
ectodomain
protein
appar
molecular
weight
antigen
lysat
slightli
larger
supernat
indic
addit
posttransl
process
protein
intermedi
product
prior
secret
nontransfect
cell
uninfect
vero
cell
show
poxspecif
antigen
fig
addit
show
recombin
protein
success
produc
purifi
e
coli
express
system
use
synthet
gene
fig
result
also
show
protein
form
dimer
nondenatur
condit
accord
sequenc
analysi
protein
potenti
site
nglycosyl
confirm
sensit
pngase
treatment
fig
three
monthli
immun
varv
dna
vaccin
elicit
high
level
antigenspecif
igg
antibodi
respons
mice
fig
immunogen
dna
vaccin
slightli
differ
immunogen
follow
dna
vaccin
antibodi
induc
immun
codon
optim
variola
dna
vaccin
recogn
vaccinia
variola
antigen
express
supernat
transient
transfect
cell
given
polyclon
natur
immun
sera
surpris
detect
signific
differ
recognit
variola
vaccinia
antigen
elisa
fig
immun
dna
vaccin
express
two
individu
varv
imv
antigen
produc
antibodi
abl
neutral
vacv
plaqu
reduct
assay
measur
imv
antibodi
fig
level
neutral
antibodi
similar
immun
sera
elicit
individu
vacv
counterpart
similar
previou
report
vacv
imv
antigen
sakhatskyy
et
al
subunit
varv
imv
antigen
effect
intact
vaccinia
infect
elicit
imv
neutral
antibodi
current
studi
test
abil
monoand
polyval
dna
vaccin
express
varv
antigen
induc
protect
two
vacv
challeng
model
first
challeng
studi
mice
first
receiv
three
monthli
dna
immun
rest
month
receiv
anoth
boost
week
prior
challeng
ensur
complet
protect
pilot
studi
mice
inocul
intraperiton
ip
lethal
dose
pfu
vacv
wr
varv
antigenspecif
antibodi
monoval
dna
vaccin
inocul
measur
elisa
fig
dna
vaccin
express
three
varv
antigen
induc
high
titer
antibodi
immun
addit
dna
vaccin
need
boost
level
antibodi
respons
fig
indic
protect
lethal
vacv
ip
challeng
model
averag
weight
loss
surviv
mice
group
measur
fig
neg
control
mice
inocul
dna
vector
progress
lost
weight
die
day
mice
receiv
either
monoor
polyval
varv
dna
vaccin
surviv
challeng
regain
bodi
weight
mice
receiv
polyval
varv
dna
vaccin
recov
back
initi
bodi
weight
sooner
mice
receiv
monoval
dna
vaccin
fig
polyval
varv
polyval
vacv
formul
abl
achiev
similar
level
protect
fig
although
intraperiton
vacv
challeng
lead
lethal
poxviru
infect
repres
natur
aerosol
spread
viru
intranas
method
infect
requir
significantli
less
viru
produc
lethal
infect
caus
death
later
time
point
suggest
differ
virushost
interact
addit
intranas
mode
infect
repres
stringent
challeng
model
sakhatskyy
et
al
therefor
investig
efficaci
protect
subunitbas
varv
antigen
deliv
form
dna
recombin
protein
vaccin
intranas
challeng
model
intranas
challeng
studi
group
mice
receiv
biweekli
immun
either
polyval
recombin
protein
vaccin
polyval
dna
vaccin
express
antigen
fig
number
immun
reduc
two
base
excel
immun
respons
two
immun
shown
ip
challeng
studi
fig
mice
immun
vaccinia
vaccin
serv
posit
control
neg
control
group
receiv
empti
dna
vector
fig
antigenspecif
antibodi
induc
either
dna
protein
formul
immun
vaccinia
vaccin
analyz
elisa
fig
immun
polyval
recombin
varv
protein
vaccin
significantli
immunogen
immun
polyval
varv
dna
vaccin
p
fig
base
elisa
result
protein
vaccin
even
immunogen
live
vaccinia
vaccin
gener
specif
antibodi
three
test
pox
antigen
contrast
immun
polyval
dnabas
varv
vaccin
induc
margin
higher
antibodi
respons
compar
immun
vacv
except
antibodi
probabl
occur
result
low
antibodi
respons
vacv
immun
mice
mice
challeng
lethal
intranas
dose
vacv
wr
pfu
two
week
nd
immun
mice
control
group
die
day
fig
mice
receiv
either
polyval
recombin
varv
protein
vaccin
vaccinia
vaccin
immun
fulli
protect
indic
surviv
rate
follow
intranas
challeng
fig
two
immun
polyval
dna
vaccin
induc
partial
protect
mice
surviv
day
fig
protein
dna
subunit
vaccin
formul
induc
statist
signific
greater
level
protect
compar
vector
control
group
respect
determin
kaplan
meier
surviv
test
past
year
progress
made
establish
use
subunitbas
smallpox
vaccin
deliv
form
dna
plasmid
hooper
et
al
hooper
custer
thompson
hooper
et
al
hooper
et
al
pulford
et
al
sakhatskyy
et
al
recombin
protein
davi
et
al
fang
et
al
fogg
et
al
galmich
et
al
heraud
et
al
xiao
et
al
induc
antibodi
protect
poxviru
infect
made
possibl
identif
immunogen
protect
vaccinia
viru
imvspecif
antigen
eg
eevspecif
antigen
eg
antigen
shown
immunogen
protect
vacv
infect
mice
fogg
et
al
galmich
et
al
hooper
et
al
hooper
et
al
pulford
et
al
sakhatskyy
et
al
xiao
et
al
ectromelia
viru
ectv
xiao
et
al
monkeypox
viru
nonhuman
primat
heraud
et
al
hooper
et
al
despit
great
progress
previou
studi
use
antigen
gene
clone
vacv
monkeypox
viru
rather
varv
induc
broad
protect
antibodi
respons
mainli
due
safeti
concern
use
varv
model
difficulti
produc
varv
infect
speci
human
nonhuman
primat
although
sequenc
similar
virus
ie
vacv
monkeypox
viru
varv
complet
ident
recent
studi
properti
vaccinia
viru
eev
protein
variola
ortholog
compar
order
determin
whether
better
choic
subunit
vaccin
smallpox
studi
found
panel
monoclon
antibodi
cross
react
protein
least
eev
neutral
block
comet
format
aldazcarrol
current
technolog
becom
possibl
produc
synthet
gene
sequenc
base
known
varv
protein
sequenc
may
immunolog
desir
produc
immun
respons
smallpox
infect
gene
anoth
pox
viru
could
argu
varvbas
antigen
compat
invad
smallpox
infect
vacv
antigen
although
definit
proof
obtain
varv
challeng
studi
readili
avail
due
secur
control
varv
reagent
current
studi
produc
subunitbas
smallpox
vaccin
base
three
varv
protect
antigen
ortholog
imv
antigen
eev
antigen
vacv
sequenc
three
varv
protein
homolog
ident
vacv
antigen
sequenc
three
amino
acid
differ
exist
amino
acid
differ
amino
acid
differ
vacv
antigen
shown
elicit
good
level
protect
intranas
vacv
challeng
pulford
et
al
report
show
whether
dna
recombin
protein
vaccin
base
varv
protect
antigen
abl
induc
neutral
antibodi
protect
vacv
show
immun
codon
optim
monoval
dna
vaccin
express
varv
antigen
elicit
antibodi
abl
neutral
vacv
measur
plaqu
reduct
assay
furthermor
varv
antigen
given
combin
induc
neutral
respons
similar
produc
vacv
counterpart
administ
combin
data
shown
increas
immunogen
administr
combin
antigen
compar
administ
monoval
formul
consist
studi
done
vacv
antigen
immun
dna
vaccin
encod
singl
vacv
membran
protein
induc
modest
antivacv
reactiv
pulford
et
al
compar
antigen
given
combin
hooper
et
al
hooper
custer
thompson
mice
vaccin
polyval
ie
varv
antigen
dna
vaccin
protect
intraperiton
challeng
vacv
challeng
administ
intranas
mice
immun
either
polyval
recombin
protein
dna
vaccin
protect
furthermor
observ
two
immun
proteinbas
subunit
vaccin
effect
dna
vaccin
elicit
higher
antibodi
respons
better
protect
dose
rang
test
current
studi
adjuv
use
protein
immun
sinc
current
studi
design
compar
differ
dna
protein
base
varv
vaccin
dedic
studi
especi
nonhuman
primat
need
identifi
qualit
quantit
differ
immunogen
protect
efficaci
two
type
varv
vaccin
summari
vaccin
base
antigen
varv
viru
confer
protect
immun
intranas
intraperiton
challeng
vaccinia
viru
induc
neutral
antibodi
vacv
given
decreas
crossreact
vacv
antigen
antigen
variola
major
aldazcarrol
studi
demonstr
feasibl
variola
major
antigenbas
vaccin
produc
may
potenti
confer
match
immun
respons
andor
greater
protect
follow
exposur
varv
result
studi
show
appar
advantag
substitut
origin
varv
antigen
ortholog
less
virul
poxvirus
indic
similar
level
neutral
antibodi
level
protect
vacv
challeng
varv
antigenbas
vaccin
develop
studi
ortholog
vacv
antigen
result
current
studi
suggest
futur
effort
develop
subunitbas
smallpox
vaccin
may
better
suit
focu
optim
condit
necessari
elicit
immunolog
respons
variola
major
protect
antigen
rather
vaccinia
viru
western
reserv
strain
vaccinia
viru
vacvwr
provid
dr
lisa
selin
univers
massachusett
medic
school
propag
vero
cell
clarifi
cell
lysat
use
western
blot
analysi
elisa
vacv
stock
challeng
prepar
cell
selin
nahil
welsh
purifi
serum
contamin
centrifug
sucros
gradient
chen
et
al
viral
titer
assay
perform
vero
cell
selin
nahil
welsh
individu
variola
varv
gene
modifi
codon
usag
synthes
base
variola
major
varvind
sequenc
sequenc
orthopoxvirus
deriv
ncbi
genom
databas
align
use
macvector
dna
insert
subclon
immedi
cmv
immedi
earli
ie
promot
wang
et
al
varv
dna
vaccin
report
studi
addit
human
tissu
plasminogen
activ
tpa
sequenc
use
enhanc
antigen
express
base
previou
report
pcr
amplifi
varv
gene
subclon
vector
downstream
tpa
leader
sequenc
alreadi
includ
vector
wang
et
al
dna
vaccin
plasmid
transform
e
coli
strain
confirm
restrict
digest
dna
sequenc
larg
amount
dna
plasmid
prepar
mega
purif
kit
qiagen
valencia
ca
report
varv
antigen
relat
vaccin
refer
recombin
varv
protein
refer
vacv
antigen
refer
histidinetag
antigen
gene
sequenc
vaccinia
variola
virus
clone
vector
invitrogen
construct
transform
compet
cell
express
transform
cell
grown
overnight
inocul
lb
medium
cultur
grown
cell
densiti
measur
reach
od
rang
isopropyl
iptg
ad
reach
final
concentr
mm
induct
protein
express
cell
harvest
hour
later
lyse
sonic
recombin
protein
load
onto
ni
column
qiagen
accord
manufactur
recommend
wash
unbound
protein
imidazol
target
protein
elut
imidazol
urea
lysi
buffer
purifi
protein
refold
dialysi
phosphatebuff
salin
protein
concentr
puriti
determin
sd
gel
six
eight
week
old
femal
balbc
mice
purchas
tacon
farm
germantown
ny
hous
depart
anim
medicin
univers
massachusett
medic
school
umm
accord
iacuc
ibc
approv
protocol
anim
immun
helio
gene
gun
biorad
shave
abdomin
skin
previous
report
wang
et
al
two
dna
immun
schedul
use
report
see
figur
legend
detail
mous
receiv
monthli
biweekli
immun
six
dna
shot
per
immun
immunogen
studi
mice
per
group
challeng
studi
group
consist
mice
blood
sampl
collect
periorbit
prior
first
immun
week
immun
mice
immun
vacv
receiv
pfu
vacv
pb
intraderm
inocul
ear
pinna
month
challeng
tschark
read
smith
tschark
smith
mice
immun
protein
receiv
biweekli
immun
purifi
recombin
protein
per
inject
pb
emulsifi
incomplet
freund
adjuv
cell
transient
transfect
calcium
chlorid
coprecipit
method
use
plasmid
dna
cell
dish
cell
harvest
h
later
supernat
cell
lysat
collect
elisa
western
blot
assay
supernat
multipl
dish
pool
amount
antigen
determin
coomassi
blue
stain
sdspolyacryamid
gel
electrophoresi
sdspage
gel
vaccinia
viru
antigenspecif
igg
respons
immun
mice
measur
elisa
use
individu
mous
sera
anim
group
elisa
plate
coat
antigen
harvest
cell
transient
transfect
dna
vaccin
plasmid
incub
overnight
wyatt
et
al
serial
dilut
mous
sera
ad
well
assay
duplic
block
plate
incub
biotinyl
antimous
igg
vector
laboratori
burlingam
ca
dilut
per
well
follow
horseradish
peroxidaseconjug
streptavidin
vector
laboratori
dilut
final
develop
sigmaaldrich
st
loui
mo
solut
per
well
reaction
stop
ad
h
plate
read
amount
transient
express
antigen
ng
protein
load
sdspolyacryamid
gel
electrophoresi
sdspage
transfer
onto
pvdf
membran
biorad
hercul
ca
incub
overnight
block
buffer
iblock
pb
membran
incub
dilut
rabbit
sera
immun
correspond
dna
vaccin
wash
blot
incub
alkalin
phosphataseconjug
goat
antirabbit
igg
tropix
bedford
dilut
hour
room
temperatur
signal
detect
use
chemiluminesc
westernlight
kit
tropix
bedford
glycosyl
studi
peptid
nglycosidas
f
pngasef
new
england
biolab
beverli
ad
denatur
sampl
prepar
supernat
transient
transfect
cell
per
manufactur
specif
incub
overnight
sampl
load
onto
sdspage
analyz
western
blot
describ
fifti
percent
plaqu
reduct
titer
determin
standard
techniqu
frey
et
al
briefli
sera
immun
anim
heat
inactiv
min
serial
dilut
antibodi
incub
pfu
vacv
hour
confluent
vero
cell
monolay
infect
antibodyviru
mixtur
hour
wash
pb
incub
liquid
overlay
day
monolay
stain
crystal
violet
sigma
min
plaqu
count
neutral
calcul
percentag
number
plaqu
count
reduc
test
serum
per
assay
compar
mean
number
plaqu
count
three
viru
control
without
sera
assay
age
match
femal
balbc
mice
per
group
use
experi
challeng
conduct
two
week
last
immun
ip
challeng
studi
mice
anesthet
intramuscularli
ketaminexylazin
mgkg
inject
intraperiton
pfu
vacvwr
pb
intranas
challeng
mice
administ
pfu
vacvwr
pb
intranas
inocul
mice
weigh
observ
daili
previous
describ
selin
nahil
welsh
death
end
follow
challeng
record
experi
done
complianc
protocol
approv
iacuc
ibc
umm
test
perform
use
epi
softwar
window
avail
cdc
web
site
surviv
curv
analyz
use
kaplanmei
test
comparison
mean
percentag
bodyweight
chang
differ
group
day
challeng
mean
antibodi
titer
perform
use
unpair
twotail
student
ttest
microsoft
excel
softwar
version
consult
biostatistician
signific
level
set
p
sequenc
analysi
select
protect
variola
major
vaccinia
antigen
amino
acid
sequenc
protein
encod
wr
cop
strain
vaccinia
viru
encod
variola
compar
number
top
amino
acid
posit
amino
acid
differ
strain
shown
bold
amino
acid
shown
ident
virus
present
dot
western
blot
analysi
transient
express
protein
cell
lysat
l
cultur
supernat
cell
transfect
respect
variola
major
antigenexpress
dna
vaccin
recombin
variola
major
protein
produc
ecoli
also
includ
analysi
vaccinia
wr
strain
grown
vero
cell
includ
posit
control
empti
dna
vaccin
vector
includ
neg
control
protein
glycosyl
express
vero
cell
subject
pngase
treatment
recognit
variola
major
vaccinia
antigen
elisa
use
polyval
mous
serum
induc
combin
three
dna
vaccin
express
variola
major
antigen
curv
averag
sera
assay
mice
receiv
three
monthli
immun
panel
show
one
pair
ortholog
antigen
variola
vaccinia
neutral
antibodi
activ
vaccinia
intracellular
matur
viru
imv
measur
plaqu
reduct
test
sera
collect
balbc
mice
monthli
immun
dna
vaccin
express
either
individu
vaccinia
antigen
individu
variola
antigen
sera
mice
immun
vacv
serv
posit
control
sera
group
receiv
empti
dna
vaccin
vector
use
neg
control
data
shown
averag
titer
mice
per
group
variola
antigenspecif
antibodi
respons
protect
lethal
intraperiton
ip
vacv
challeng
balbc
mice
immun
dna
vaccin
express
variola
antigen
elisa
analysi
end
titrat
igg
titer
mous
sera
immun
monoval
dna
vaccin
express
either
autolog
antigen
express
cell
sera
collect
one
two
three
monthli
dna
immun
data
shown
geometr
mean
titer
anim
b
protect
ip
vacv
challeng
mice
immun
either
monoval
combin
dna
vaccin
mice
immun
either
posit
control
vaccinia
wr
neg
control
empti
dna
vaccin
vector
also
includ
bodi
weight
loss
shown
percentag
prechalleng
weight
measur
daili
curv
show
group
averag
weight
loss
mice
per
group
challeng
c
protect
ip
vacv
challeng
mice
immun
either
combin
vaccinia
dna
vaccin
combin
variola
dna
vaccin
empti
dna
vaccin
vector
neg
control
bodi
weight
loss
shown
percentag
prechalleng
weight
measur
daili
curv
show
group
averag
weight
loss
standard
deviat
mice
per
group
challeng
immunogen
protect
efficaci
polyval
recombin
variola
protein
vaccin
polyval
dna
vaccin
express
variola
antigen
elisa
analysi
end
titrat
igg
titer
antigen
immun
mice
sera
data
shown
geometr
mean
titer
group
per
group
two
biweekli
immun
anim
immun
either
combin
recombin
protein
protein
combin
three
dna
vaccin
express
antigen
dna
control
group
anim
receiv
onetim
vaccinia
wr
immun
vacv
protein
immun
elicit
significantli
higher
antibodi
compar
dna
immun
indic
p
b
protect
lethal
intranas
challeng
vacv
wr
mice
receiv
two
biweekli
immun
either
combin
three
recombin
variola
protein
combin
three
dna
vaccin
express
posit
control
anim
receiv
onetim
vaccinia
wr
immun
neg
control
anim
receiv
three
immun
empti
dna
vaccin
vector
curv
show
daili
percentag
surviv
group
mice
per
group
challeng
